Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69,213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design.
Fulcher GR, Jarlov H, Piltoft JS, Singh KP, Liu L, Mohamed M, Nicodemus NA Jr, Al-Jaser SJ, Kok A. Fulcher GR, et al. Among authors: liu l. Endocrine. 2021 Dec;74(3):530-537. doi: 10.1007/s12020-021-02887-8. Epub 2021 Oct 12. Endocrine. 2021. PMID: 34637072 Free PMC article.
Correction: ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in realworld settings: rationale and design.
Fulcher GR, Jarlov H, Piltoft JS, Singh KP, Liu L, Mohamed M, Nicodemus NA Jr, Al-Jaser SJ, Kok A. Fulcher GR, et al. Among authors: liu l. Endocrine. 2022 Mar;75(3):964. doi: 10.1007/s12020-021-02956-y. Endocrine. 2022. PMID: 34919203 Free PMC article. No abstract available.
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
Pei Y, Agner BR, Luo B, Dong X, Li D, Liu J, Liu L, Liu M, Lu Y, Nishida T, Xu X, Mu Y. Pei Y, et al. Among authors: liu j, liu m, liu l. Diabetes Obes Metab. 2021 Dec;23(12):2687-2696. doi: 10.1111/dom.14522. Epub 2021 Aug 31. Diabetes Obes Metab. 2021. PMID: 34387411 Free PMC article. Clinical Trial.
DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
Wang W, Agner BFR, Luo B, Liu L, Liu M, Peng Y, Qu S, Stachlewska KA, Wang G, Yuan G, Zhang Q, Ning G. Wang W, et al. Among authors: liu m, liu l. J Diabetes. 2022 Jun;14(6):401-413. doi: 10.1111/1753-0407.13286. J Diabetes. 2022. PMID: 35762390 Free PMC article. Clinical Trial.
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Mukohara T, et al. Among authors: liu l. Nat Med. 2024 Jun 24. doi: 10.1038/s41591-024-03129-w. Online ahead of print. Nat Med. 2024. PMID: 38914862 No abstract available.
69,213 results
You have reached the last available page of results. Please see the User Guide for more information.